Clinical Trials · NCT03820830
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Enrollment
- 405
- Start date
- Aug 2019
- Locations
- 53 sites, 6 countries
- Primary endpoint
- Duration of invasive disease free survival of all randomized participants.